Elanco Animal Health Incorporated (ELAN) Q3 FY2026 earnings

Reported results

• Total revenue was $1,265 million, an increase of 11% on a reported basis and 9% on an organic constant currency basis.
• Reported Net Income was $18 million (Reported EPS of $0.04), compared to reported net loss of $34 million (Reported EPS of $(0.07)) in the third quarter of 2025.
• Adjusted Net Income was $136 million, representing Adjusted EPS of $0.27.
• Adjusted EBITDA was $243 million, an increase of 23%, with an Adjusted EBITDA Margin of 19.5%.
• GAAP reported gross profit was $720 million (gross margin percentage of 56.9%) and adjusted gross profit was $699 million (adjusted gross margin percentage of 56.1%).

Guidance

• Full Year 2026 revenue guidance is $5,155 million to $5,180 million (or $5.155 billion to $5.18 billion).
• Full Year 2026 Adjusted EBITDA guidance is $1,050 million to $1,065 million (or $1.05 billion to $1.065 billion).
• Full Year 2026 Adjusted EPS guidance is $1.17 to $1.20.
• Full Year 2026 innovation revenue target is raised to $1.275 billion.
• Fourth Quarter 2026 revenue guidance is $1,190 million to $1,215 million.
• Fourth Quarter 2026 Adjusted EBITDA guidance is $185 million to $200 million.
• Fourth Quarter 2026 Adjusted EPS guidance is $0.16 to $0.19.

Price and volatility reaction

The stock moved +8.7% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -10.8 vol points across the event (constant-maturity series — not the front-week crush).

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.